Moderna Inc. has agreed to do a placebo-controlled trial of its new Covid vaccine that was recently approved by US regulators ...

By Stephanie Brown HealthDay ReporterTUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...

A new COVID variant - NB 1.8.1 - is creeping across California; here are the symptoms to watch for, and vaccinations you'll need to take.

The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...

Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.

The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It’s made in a way that allows ...

From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.

Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ETCompany ParticipantsStephen Hoge - PresidentConference ...

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it.